KEPIVANCE

LOE Approaching

palifermin

BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
18

Mechanism of Action

(FGF) family that binds to the KGF receptor. Binding of KGF to its receptor has been reported to result in proliferation, differentiation, and migration of epithelial cells. The KGF receptor, one of four receptors in the FGF family, has been reported to be present on epithelial cells in many…

Pharmacologic Class:

Mucocutaneous Epithelial Cell Growth Factor

Clinical Trials (5)

NCT01746849Phase 2Active Not Recruiting

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Started Dec 2012
NCT02037347Phase 1/2Terminated

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Started Oct 2010
NCT01163097Phase 1Completed

Study to Characterize the Effect of Heparin on Palifermin Activity

Started Jul 2010
NCT00570999Phase 2Withdrawn

Palifermin After Haploidentical PBSCT

Started Feb 2008
0
Non-Hodgkin's Lymphoma or Hodgkin's DiseaseAcute LeukaemiaMyelodysplastic Syndrome+2 more
NCT00540332Phase 1/2Withdrawn

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy

Started Oct 2007
0
Head and Neck Cancer